For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Tempest Therapeutics, Inc. ( (TPST)) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to its investors. Tempest Therapeutics, Inc. is a ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company ...

On Monday, Tempest Therapeutics Inc (TPST) stock saw a modest uptick, ending the day at $1.1 which represents a slight increase of $0.01 or 0.92% from the prior close of $1.09. The stock opened at ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...